Search - tctmd.com

Displaying 61 - 80 of 106

Sort: Relevancy | Date

News Conference News ESC 2018

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

L.A. McKeown

August 31, 2018

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Todd Neale

August 27, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Daily News

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Michael O'Riordan

May 10, 2018

News Daily News

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

Shelley Wood

April 06, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

Advertisement

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

One in Five Acute MI Patients Drop Statins Within 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content